Amgen | AMGN

Stock Price
415.21
Daily Change
-2.63 -0.63%
Monthly
15.88%
Yearly
40.05%
Q3 Forecast
406.28

EPS Reference Time Actual Consensus Previous
2026-11-03 FY2026Q3 PM 5.76 5.64
2026-08-04 FY2026Q2 PM 6.29 5.59 6.02
2026-04-30 FY2026Q1 PM 5.15 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58



Peers Price Chg Day Year Date
Takeda 5,525.00 -86.00 -1.53% 23.16% Aug/17
AbbVie 249.46 -1.36 -0.54% 20.69% Aug/14
Agios Pharmaceuticals 33.56 0.09 0.27% -9.32% Aug/14
ALKERMES 49.06 -0.39 -0.79% 68.88% Aug/14
Amgen 415.21 -2.63 -0.63% 40.05% Aug/14
Biogen 209.83 -0.82 -0.39% 51.39% Aug/14
BioMarin Pharmaceutical 67.36 -1.17 -1.71% 17.07% Aug/14
Bristol-Myers Squibb 63.83 -0.82 -1.27% 31.77% Aug/14
Coherus Biosciences 1.20 0.06 5.26% 14.29% Aug/14
Exelixis 51.24 0.63 1.24% 33.75% Aug/14

Indexes Price Day Year Date
US500 7791 -13.23 -0.17% 20.81% Aug/17
USND 26729 -73.86 -0.28% 23.61% Aug/14
US30 53667 -107.58 -0.20% 19.49% Aug/17
US100 30087 -38.36 -0.13% 26.88% Aug/17

Amgen traded at $415.21 this Friday August 14th, decreasing $2.63 or 0.63 percent since the previous trading session. Looking back, over the last four weeks, Amgen lost 15.88 percent. Over the last 12 months, its price rose by 40.05 percent. Looking ahead, we forecast Amgen to be priced at 406.28 by the end of this quarter and at 380.64 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Stock Price Hits 11-week High
Amgen shares increased to 358.73 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.78%, and in the last 12 months, it increased 28.52%.
2026-06-25
Amgen Stock Price Hits 5-week High
Amgen shares increased to 345.87 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.8%, and in the last 12 months, it increased 20.51%.
2026-06-04
Amgen Stock Price Hits 14-week Low
Amgen shares decreased to 334.00 USD, the lowest since January 2026. Over the past 4 weeks, Amgen lost 3.77%, and in the last 12 months, it increased 16.38%.
2026-04-29